Key result
Baseline digoxin use in patients with atrial fibrillation without heart failure was associated with an increased risk of sudden cardiac death.
Why the study?
Does digoxin use increase the risk of sudden cardiac death and mortality in patients with atrial fibrillation with or without heart failure?
Observational (n=21,105)
Yes
Does digoxin use increase the risk of sudden cardiac death and mortality in patients with atrial fibrillation with or without heart failure?
Digoxin use in patients with atrial fibrillation is associated with an increased risk of sudden cardiac death and other mortality outcomes, regardless of the presence of heart failure.
Answers are grounded in this paper and cite their sources.
Digoxin may warrant caution in AF; leaves open whether RCTs can confirm mortality signals after HF adjustment.
Background Digoxin is widely used in patients with atrial fibrillation despite the lack of randomized controlled trials. Observational studies report conflicting results regarding its association with mortality, perhaps because of residual confounding by the presence of heart failure ( HF ). Methods and Results In the ENGAGE AF ‐ TIMI 48 (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation‐Thrombolysis in Myocardial Infarction 48) trial, clinical outcomes of patients with atrial fibrillation with and without HF were examined by baseline digoxin use during a median follow‐up of 2.8 years. HF was defined at baseline as prior or current clinical stage C or D HF . Of 21 105 patients enrolled, 6327 (30%) were treated with digoxin at baseline. Among patients without HF (n=8981), digoxin use (20%) was independently associated with sudden cardiac death (adjusted hazard ratio, 1.51; 95% CI, 1.10–2.08), with no significant interaction by age, sex, left ventricular ejection fraction, renal function, or concomitant medications ( P >0.05 for each). Consistent results were observed using propensity matching (adjusted hazard ratio for sudden cardiac death, 1.90; 95% CI , 1.36–2.65). Among patients with HF (n=12 124), digoxin use (37%) was associated with an increase in all‐cause death, cardiovascular death, sudden cardiac death, and death caused by HF /cardiogenic shock ( P <0.01 for each), but not with noncardiovascular death, stroke/systemic embolism, or myocardial infarction. Conclusions In this observational analysis of patients with atrial fibrillation without investigator‐reported HF , digoxin use was significantly associated with sudden cardiac death. While residual confounding cannot be excluded, the association between digoxin use and worse clinical outcomes highlights the need to examine digoxin use, particularly when prescribed to control heart rate in patients with atrial fibrillation in a randomized trial. Clinical Trial Registration URL : http://www.clinicaltrials.gov . Unique identifier: NCT 00781391.
No takes yet. Share an insight, caveat, or question.
Eisen et al. (2017) conducted an observational in Atrial Fibrillation (n=21,105). Digoxin vs. No digoxin was evaluated on Sudden cardiac death in patients without heart failure (HR 1.51, 95% CI 1.10-2.08, p=0.01). Baseline digoxin use in patients with atrial fibrillation without heart failure was associated with an increased risk of sudden cardiac death.
Synapse has enriched 10 related papers. Consider them for comparative context: